Incyte Appointments Dave Gardner, EVP & Chief Strategy Officer

Incyte named Dave Gardner Executive Vice President and Chief Strategy Officer (CSO) effective September 22, 2025. In his new role, Gardner will serve as a key member of the Executive Leadership Team and be responsible for the company’s strategy and business development.

After nine years as a key member of the Incyte leadership team, Vijay Iyengar, M.D., Executive Vice President and Head of Global Medical Affairs and Product and Partnership Strategy, will be retiring from Incyte and will continue to provide transitional support to Gardner through the end of the year.

Gardner has over 20 years of experience in pharmaceutical and biotechnology investing and advising. He most recently served as Partner on the Therapeutics Team at Rock Springs Capital Management, leading strategy across Oncology, Neurology, Immunology, and Rare Diseases. Before that, Gardner spent a decade at BlackRock as Vice President and Equity Research Analyst, where he was responsible for the Health Care sector. 

“Dave possesses a unique combination of business acumen, scientific knowledge, and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development,” said Bill Meury, President and CEO, Incyte. “Dave will play a pivotal role in developing a coherent and executable long-term growth strategy for the company and ensuring our portfolio decisions, business development, and strategic partnerships position Incyte for sustainable value creation.”